Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  La Jolla Pharmaceutical Company    LJPCD

SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

LA JOLLA PHARMACEUTICAL COMPANY : REVERSE SPLIT: 1 for 50

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2014 CEST
REVERSE SPLIT: 1 for 50


© Factset 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LA JOLLA PHARMACEUTICAL CO
05/23 LA JOLLA PHARMACEUTICAL : posts mixed bag of phase 3 data, raising hopes of FDA ..
05/22 LA JOLLA PHARMACEUTICAL COMPANY (NAS : LJPC) Files An 8-K Other Events
05/22 LA JOLLA PHARMACEUTICAL CO : Other Events, Financial Statements and Exhibits (fo..
05/22 LA JOLLA PHARMACEUTICAL : Results of ATHOS‑3 Phase 3 Study of LJPC-501 Pub..
05/21 LA JOLLA PHARMACEUTICAL : Results of ATHOS-3 Phase 3 Study of LJPC-501 Published..
05/18 LA JOLLA PHARMACEUTICAL COMPANY (NAS : LJPC) Files An 8-K Other Events
05/18 LA JOLLA PHARMACEUTICAL CO : Other Events (form 8-K)
05/01 LA JOLLA PHARMACEUTICAL COMPANY (NAS : LJPC) Files An 8-K Results of Operations ..
05/01 LA JOLLA PHARMACEUTICAL CO : Results of Operations and Financial Condition, Fina..
04/28 LA JOLLA PHARMACEUTICAL : posts 1Q loss
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2017 0,27 M
EBIT 2017 -93,6 M
Net income 2017 -102 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 2 375x
Capi. / Sales 2018 17,1x
Capitalization 642 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 55,4 $
Spread / Average Target 91%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George Francis Tidmarsh President, CEO, Secretary & Director
Kevin C. Tang Chairman
Jennifer Carver Senior Vice President-Operations
Dennis M. Mulroy Chief Financial & Accounting Officer
Lakhmir S. Chawla Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LA JOLLA PHARMACEUTICA..0.00%642
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.89%91 185
GILEAD SCIENCES, INC.-9.93%84 284
REGENERON PHARMACEUTIC..23.99%48 380
ACTELION LTD24.38%30 602
More Results